Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Journal for Immunotherapy of Cancer
|
June 6, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B Holmgaard, David A Schaer, Yanxia Li, et al.
Cancer Research
|
January 15, 2011
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases
Bruce W Konicek, Jennifer R Stephens, Ann M McNulty, et al.
Cancer Research
|
August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
Jeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.
Oncotarget
|
February 21, 2020
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
Wayne D Blosser, Jack A Dempsey, Ann M McNulty, et al.
Cell Reports
|
March 15, 2018
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A Schaer, Richard P Beckmann, Jack A Dempsey, et al.
Oncotarget
|
February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
Jonathan M Yingling, William T McMillen, Lei Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Caitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Journal of Medicinal Chemistry
|
July 23, 2004
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3
Thomas A Engler, James R Henry, Sushant Malhotra, et al.
Cancer Cell
|
December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Scientific Reports
|
October 20, 2018
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models
Harold B Brooks, Timothy I Meier, Sandaruwan Geeganage, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Journal for Immunotherapy of Cancer
|
June 6, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B Holmgaard, David A Schaer, Yanxia Li, et al.
Cancer Research
|
January 15, 2011
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases
Bruce W Konicek, Jennifer R Stephens, Ann M McNulty, et al.
Cancer Research
|
August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
Jeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.
Oncotarget
|
February 21, 2020
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
Wayne D Blosser, Jack A Dempsey, Ann M McNulty, et al.
Cell Reports
|
March 15, 2018
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A Schaer, Richard P Beckmann, Jack A Dempsey, et al.
Oncotarget
|
February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
Jonathan M Yingling, William T McMillen, Lei Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Caitlin D Lowery, Michele Dowless, Matthew Renschler, et al.
Journal of Medicinal Chemistry
|
July 23, 2004
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3
Thomas A Engler, James R Henry, Sushant Malhotra, et al.
Cancer Cell
|
December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Scientific Reports
|
October 20, 2018
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models
Harold B Brooks, Timothy I Meier, Sandaruwan Geeganage, et al.
Page
of 4